Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Change in Accured Expenses data on record, last reported at $21.3 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 97.5% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $16.2 million, down 24.04%, while the annual FY2025 figure was $16.2 million, 24.04% down from the prior year.
  • Change in Accured Expenses reached $21.3 million in Q4 2025 per VRDN's latest filing, up from $4.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $21.3 million in Q4 2025 and bottomed at -$15.8 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $2.6 million, with a median of $2.9 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: surged 1610.78% in 2021, then tumbled 1671.03% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.6 million in 2021, then surged by 269.25% to $6.0 million in 2022, then dropped by 24.48% to $4.5 million in 2023, then soared by 138.05% to $10.8 million in 2024, then soared by 97.5% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $21.3 million in Q4 2025, $4.6 million in Q3 2025, and $6.1 million in Q2 2025.